Royce & Associates LP Grows Holdings in Zevra Therapeutics, Inc. $ZVRA

Royce & Associates LP increased its position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 25.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 865,822 shares of the company’s stock after purchasing an additional 174,583 shares during the quarter. Royce & Associates LP’s holdings in Zevra Therapeutics were worth $7,758,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ZVRA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Zevra Therapeutics by 6.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock worth $238,000 after purchasing an additional 1,812 shares during the last quarter. Strs Ohio purchased a new position in Zevra Therapeutics during the first quarter worth about $125,000. Creative Planning purchased a new position in Zevra Therapeutics during the second quarter worth about $92,000. Rhumbline Advisers boosted its holdings in Zevra Therapeutics by 11.6% during the second quarter. Rhumbline Advisers now owns 83,221 shares of the company’s stock worth $733,000 after purchasing an additional 8,636 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new position in Zevra Therapeutics during the second quarter worth about $255,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Trading Up 4.1%

Shares of NASDAQ:ZVRA opened at $11.40 on Friday. The company has a 50 day moving average of $10.10 and a 200 day moving average of $9.29. The stock has a market cap of $673.97 million, a P/E ratio of 5.73 and a beta of 0.88. Zevra Therapeutics, Inc. has a 12 month low of $7.16 and a 12 month high of $13.16.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.06 by $0.12. The company had revenue of $36.22 million during the quarter, compared to analysts’ expectations of $31.96 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. On average, equities analysts forecast that Zevra Therapeutics, Inc. will post 0.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on ZVRA. Weiss Ratings lowered shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Friday, May 22nd. Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, April 11th. Guggenheim lifted their price objective on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Finally, BTIG Research began coverage on shares of Zevra Therapeutics in a research report on Monday, March 16th. They issued a “buy” rating and a $23.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Zevra Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.33.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.